不同剂量阿托伐他汀对缺血性脑血管病患者临床生化指标的影响

发布时间：2018-05-08 03:27

  本文选题：阿托伐他汀 + 缺血性脑血管病　； 参考：《中国实用神经疾病杂志》2016年23期

【摘要】：目的探讨不同剂量阿托伐他汀对缺血性脑血管病患者临床生化指标的影响。方法采用随机双盲对照方法,收集我院100例缺血性脑血管患者,随机分成2组,实验组(50例)在常规治疗缺血性脑血管病基础上给予阿托伐他汀40mg/d治疗,对照组(50例)在常规治疗缺血性脑血管病基础上给予阿托伐他汀20mg/d治疗,疗程均为3个月。检测并对比2组治疗前后临床生化指标。结果 2组三酰甘油(TG)、胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、同型半胱氨酸(Hcy)、C反应蛋白(CRP)水平与治疗前比较均显著下降(P0.05);同时,2组高密度脂蛋白胆固醇(HDL-C)与治疗前比较明显升高(P0.05)。实验组空腹血糖(FBS)、糖化血红蛋白(HbA1c)水平与治疗前比较明显升高(P0.05),对照组无明显变化(P0.05)。结论不同剂量的阿托伐他汀治疗3个月后均能有效改善血脂水平,而高剂量(40mg/d)阿托伐他汀可能导致血糖异常,低剂量(20mg/d)阿托伐他汀对患者血糖升高无影响,对于缺血性脑血管病患者采用低剂量阿托伐他汀治疗更安全有效。
[Abstract]:Objective to investigate the effects of different doses of Atto vastatin on clinical biochemical indexes in patients with ischemic cerebrovascular disease. Methods 100 patients with ischemic cerebrovascular diseases in our hospital were randomly divided into two groups, the experimental group (n = 50) and the control group (n = 50). Atto vastatin 40mg/d was given on the basis of routine treatment of ischemic cerebrovascular disease. The control group (n = 50) was treated with Atto vastatin 20mg/d for 3 months on the basis of routine treatment of ischemic cerebrovascular disease. The clinical biochemical indexes before and after treatment were detected and compared between the two groups. Results the levels of TGG, TC, LDL-CU, Hcysteine C reactive protein (CRP) in the two groups were significantly decreased compared with those before treatment, and HDL-C in the two groups were significantly increased compared with those before treatment (P 0.05), and the levels of HDL-C in the two groups were significantly higher than those in the control group (P < 0.05), while the levels of HDL-C in the two groups were significantly higher than those in the control group (P < 0.05). The levels of FBSN, HbA1c) in the experimental group were significantly higher than those before treatment, but there was no significant change in the control group. Conclusion different doses of Atto vastatin can effectively improve blood lipid level after 3 months of treatment, while high dose of 40 mg / d) Atto vastatin may lead to abnormal blood glucose. Low dose of 20 mg / d Atto vastatin has no effect on the increase of blood glucose in patients. It is more safe and effective to treat ischemic cerebrovascular disease with low dose Atto vastatin.
【作者单位】： 重庆三峡中心医院神经内科;
【分类号】：R743.3
，

本文编号：1859772